Gileada s Single Tablet HIV Regimen Stribild Demonstrates Durable...

Gilead Sciences, Inc. today announced three-year efficacy and safety results from two pivotal Phase 3 studies evaluating the once-daily single tablet regimen Stribild among treatment-naive patients with HIV-1 infection.

http://www.businesswire.com/news/topix/20131016005546/en